Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?

Campbell, Courtney M; Kahwash, Rami

Campbell, Courtney M; Kahwash, Rami.

Campbell CM; Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus.
Kahwash R; Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus.

Circulation ; 141(22): 1739-1741, 2020 06 02.

Article in English | MEDLINE | ID: covidwho-48027

Subject(s)

Complement System Proteins; Thrombosis; Betacoronavirus; COVID-19; China; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2

Keywords

COVID-19; atypical hemolytic-uremic syndrome; complement; immunosuppressive agents; thrombotic microangiopathies

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombosis / Complement System Proteins Limits: Humans Country/Region as subject: Asia Language: English Journal: Circulation Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google